1.Define and execute the medicinal chemistry strategy for molecular glues, PROTACs and peptide-based degraders 2.Drive independent discovery and optimization of novel E3 ligase ligands, establishing a scalable multi-E3 roadmap across both established and newly identified E3 ligases; advance programs from target assessment through hit discovery, SAR, PCC nomination, and IND-enabling chemistry. 3. Lead degron-template mining and E3-substrate interface exploration, integrating molecular surface fingerprinting, template extraction, and AI-driven structural modeling in close partnership with the AIDD and structural biology teams. 4. Design, build, and validate high-quality DEL/CIP-DEL libraries tailored to both warhead discovery and E3-ligand identification for challenging or undruggable protein targets, enabling efficient hit generation at scale.

• PhD in Medicinal Chemistry, Chemical Biology, Structural Biology, or a related discipline. • Over 5 years of experience in small-molecule drug discovery, with deep expertise in structure-based drug design, SAR optimization and translational research. • Minimum of 2 years leading Targeted Protein Degradation (TPD) programs, including PROTACs, molecular glues, or E3 ligase modulation, with a strong track record of advancing assets from hit identification through PCC and IND- enabling studies. • Demonstrated ability to apply advanced discovery technologies, including DNA- encoded libraries (DEL/CIP-DEL), chemoproteomics, fragment-based screening, phenotypic screening and AI-driven virtual screening.